There are approx 115,000 cases of prostate cancer per year in china.
It depends on the label approved and how much a dose will cost in China and the grand pharma/Telix agreement
Eg. Lets say label allows imaging for 30% of 115,000 cases at a dose of 5,000 AUD (34,500 x 5000 = 172 mil) very rough but seems to be discounted with all eyes on the US market indication expansion
Major variables - approved label use, cost per dose, number of patients
No competition in China to my knowledge.
Of course this is just for illuccix - no other telix products that are also coming to china
DYOR
https://www.aap.com.au/aapreleases/cision20221016ae04672/
There are approx 115,000 cases of prostate cancer per year in...
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.03 |
Change
0.760(4.16%) |
Mkt cap ! $6.368B | |||
| Open | High | Low | Value | Volume |
| $18.51 | $19.05 | $18.17 | $21.27M | 1.129M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 5455 | $18.92 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.03 | 1525 | 2 |
View Market Depth
| Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
| TLX (ASX) Chart |